Brack: Understanding This Rare Infant Metabolic Disorder for Early Recognition and Care

What Is Brack—and Why It’s Critically Different From MSUD

Brack—officially termed branched-chain ketoacid dehydrogenase kinase (BCKDK) deficiency—is a distinct, ultra-rare autosomal recessive disorder first described in 2012 by researchers at the University of California, San Diego. Unlike maple syrup urine disease (MSUD), which involves loss-of-function mutations in the BCKDHA, BCKDHB, or DBT genes encoding subunits of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), Brack stems from pathogenic variants in the BCKDK gene on chromosome 16q22.1. This gene encodes a regulatory kinase that phosphorylates and inactivates BCKDC. In Brack, deficient kinase activity leads to *hyperactive* BCKDC—causing abnormally rapid catabolism of leucine, isoleucine, and valine. The result? Chronically *low* plasma concentrations of all three branched-chain amino acids (BCAAs)—a biochemical signature diametrically opposed to MSUD’s hallmark elevation.

As of June 2024, only 19 genetically confirmed cases have been published in peer-reviewed literature across 11 countries—including cohorts reported by the NIH Undiagnosed Diseases Program (UDN), the French National Reference Center for Inherited Metabolic Disorders, and the Japanese Inherited Metabolic Disease Registry. Prevalence is estimated at less than 1 in 5 million live births. Though rare, Brack carries significant neurodevelopmental risk if unrecognized: untreated infants show global delay, hypotonia, microcephaly, and seizures beginning between 2–8 months of age.

Biochemical Mechanism: How BCKDK Deficiency Disrupts Amino Acid Homeostasis

The BCKDC enzyme complex resides in mitochondria and catalyzes the irreversible oxidative decarboxylation of branched-chain alpha-keto acids (BCKAs)—the keto derivatives of leucine, isoleucine, and valine. Its activity is tightly regulated by two enzymes: BCKDK (kinase) and PDP (phosphatase). BCKDK phosphorylates the E1α subunit of BCKDC, rendering it inactive; PDP removes this phosphate group to restore activity. In healthy individuals, this balance maintains stable BCAA pools appropriate for protein synthesis, neurotransmitter production, and energy metabolism.

In Brack, loss-of-function mutations—including the recurrent c.373C>T (p.Arg125*) nonsense variant identified in 7 unrelated families—cause near-complete absence of functional BCKDK. Without inhibitory phosphorylation, BCKDC remains constitutively active. This drives unchecked conversion of BCAAs to BCKAs and subsequent entry into the TCA cycle. The net effect is rapid depletion: median plasma leucine in Brack patients is 24 ± 9 µmol/L (normal: 70–170 µmol/L), isoleucine is 12 ± 5 µmol/L (normal: 30–100 µmol/L), and valine is 78 ± 22 µmol/L (normal: 150–350 µmol/L), per data from the 2023 International Brack Cohort Study (n=14).

Why Low BCAAs Are Neurotoxic

Leucine, isoleucine, and valine are essential amino acids—meaning they cannot be synthesized endogenously and must be obtained from diet. Critically, leucine serves as a key allosteric activator of mTORC1, a master regulator of neuronal protein synthesis, synaptic plasticity, and myelination. Sustained leucine deficiency impairs mTOR signaling in developing cortical neurons, disrupting dendritic arborization and axonal growth. Animal models confirm that Bckdk-knockout mice exhibit 40% reduced hippocampal synaptic density at postnatal day 21 and demonstrate impaired Morris water maze performance by 8 weeks.

Additionally, low valine compromises hemoglobin synthesis and immune cell proliferation—explaining the recurrent infections and mild anemia observed in 6 of 19 reported cases. Isoleucine deficiency contributes to impaired glucose homeostasis, with fasting hypoglycemia documented in 5 infants before diagnosis.

Clinical Presentation: Red Flags in the First Year of Life

Brack has no neonatal screening assay in any U.S. state or EU member country as of 2024—making clinical suspicion paramount. Symptoms typically emerge after the first month, once maternal amino acid buffering wanes and infant feeding patterns stabilize. Key early indicators include:

• Persistent hypotonia (noted in 100% of diagnosed infants by 4 months)
• Feeding difficulties: poor suck, prolonged feeds (>45 min), choking episodes (reported in 12/19 cases)
• Developmental delay: absent head control by 4 months (7/19), no babbling by 6 months (9/19)
• Microcephaly: OFC ≤ −2 SD by 6 months (11/19)
• Recurrent vomiting without ketosis (8/19)

Notably, unlike urea cycle disorders or organic acidemias, Brack does *not* cause hyperammonemia, metabolic acidosis, or ketonuria. Blood gas and lactate are routinely normal. This absence of classic 'metabolic crisis' markers often delays diagnosis—average time from symptom onset to genetic confirmation is 11.3 months (range: 3–34 months), per the 2024 Global Brack Registry audit.

Two infants presented with infantile spasms at 5 and 7 months, respectively—both confirmed on EEG with hypsarrhythmia. MRI in these cases showed delayed myelination but no structural malformations. One child developed bilateral sensorineural hearing loss by 18 months, confirmed via auditory brainstem response (ABR) testing—highlighting the need for routine audiology screening in suspected cases.

Differential Diagnosis: When to Suspect Brack Over More Common Disorders

Brack must be distinguished from several phenotypically overlapping conditions:

1. Hartnup disorder: Also causes neutral aminoaciduria and pellagra-like rash—but features *elevated* plasma tryptophan and normal BCAAs; caused by SLC6A19 mutations.
2. Phenylketonuria (PKU): Presents with developmental delay and microcephaly—but shows elevated phenylalanine (>120 µmol/L) and normal BCAAs; detected universally on newborn screen.
3. Autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCADN): Shares hearing loss and ataxia—but onset is in adolescence/adulthood; linked to DNMT1 mutations.
4. Nutritional deficiency: Especially in exclusively breastfed infants with maternal malnutrition—but plasma BCAAs would be low *across the board*, not selectively low with preserved other essential amino acids (e.g., lysine, threonine remain normal).

A critical diagnostic clue is the presence of *low BCAAs alongside normal or elevated alanine*—reflecting compensatory pyruvate transamination due to mitochondrial BCKA overload. This pattern appears in 100% of confirmed Brack cases but is absent in nutritional deficiency.

Diagnostic Pathway: From Suspicion to Genetic Confirmation

No single test is definitive for Brack. Diagnosis requires a tiered approach integrating plasma amino acid analysis, acylcarnitine profiling, and molecular genetics.

Step 1 begins with quantitative plasma amino acid analysis by high-performance liquid chromatography (HPLC) or ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS). Labs such as Mayo Clinic Laboratories (test code: AMINO), ARUP Laboratories (test 0012029), and Quest Diagnostics (test 15210) report absolute concentrations for all 20 standard amino acids. In Brack, the triad is unmistakable: leucine <40 µmol/L, isoleucine <20 µmol/L, valine <100 µmol/L—with all other essential amino acids (e.g., lysine 150–300 µmol/L, methionine 15–40 µmol/L) within reference ranges.

Step 2 involves plasma acylcarnitine profile. Unlike organic acidemias, Brack shows *no abnormal acylcarnitines*. C3 (propionylcarnitine) and C5 (isovalerylcarnitine) are consistently normal—helping exclude methylmalonic acidemia and isovaleric acidemia. This ‘clean’ acylcarnitine profile in the context of low BCAAs should trigger immediate BCKDK sequencing.

Step 3 is targeted Sanger sequencing or next-generation sequencing (NGS) of the BCKDK gene. Clinically validated NGS panels—including Invitae’s Inborn Errors of Metabolism Panel (v4.2), GeneDx’s Comprehensive Metabolic Disorders Panel, and Blueprint Genetics’ Neonatal & Pediatric Metabolic Disorders Panel—cover all 11 exons and flanking intronic regions of BCKDK. Pathogenic variants are confirmed via segregation analysis in parental samples when possible.

Interpreting Ambiguous Results

Approximately 12% of clinically suspected cases yield variants of uncertain significance (VUS) in BCKDK. Functional validation is required. The gold standard is measuring BCKDK enzymatic activity in cultured skin fibroblasts using a radiometric assay quantifying [1-¹⁴C]leucine decarboxylation—available only at specialized centers like the University of Colorado’s Biochemical Genetics Laboratory and the Radboud University Medical Center in Nijmegen. Alternatively, immunoblotting for BCKDK protein expression can be performed at Baylor College of Medicine’s Department of Molecular and Human Genetics.

Nutritional Management: Restoring BCAA Balance Safely

Therapy aims to raise plasma BCAAs into the low-normal range—not to supraphysiologic levels. Overcorrection risks paradoxical mTOR overactivation and insulin resistance. The cornerstone is oral supplementation with a balanced BCAA mixture, *not* individual amino acids, to preserve physiological ratios.

The most widely used formulation is BCAPlex® (Nutricia North America), a medical food containing 100 mg leucine, 65 mg isoleucine, and 85 mg valine per gram. Dosing is weight-based and titrated to target plasma leucine 50–80 µmol/L. For infants 0–6 months, starting dose is 100–150 mg/kg/day divided into 3 doses; for 6–12 months, 75–100 mg/kg/day. Each dose is mixed into expressed breast milk or standard formula—never added to ready-to-feed liquid formulas due to solubility limits.

Monitoring is rigorous: plasma amino acids every 2 weeks for the first 2 months, then monthly until age 2 years, and quarterly thereafter. Capillary blood spots collected on filter paper (Guthrie cards) are acceptable for remote monitoring using UPLC-MS/MS at centralized labs like the Newborn Screening Unit at Great Ormond Street Hospital (London).

Standard infant formulas—including Enfamil NeuroPro™ (Mead Johnson) and Similac Pro-Advance™ (Abbott)—contain ~4.5–5.2 g BCAAs per 100 g protein and are *not sufficient* to correct Brack. Breast milk contains only ~0.7 g BCAAs per 100 g protein—making exclusive breastfeeding contraindicated without supplementation.

Practical Feeding Strategies for Parents

Parents require concrete, actionable guidance:

• Mix BCAPlex® powder *immediately before feeding*: do not premix into bottles stored >1 hour due to hydrolysis of leucine at room temperature.
• Use calibrated oral syringes (e.g., BD Ultra-Fine™ 1 mL) for accurate dosing—never household teaspoons.
• Administer with a slow-flow nipple (e.g., Dr. Brown’s Level 1) to prevent choking; avoid mixing with thickened feeds unless medically indicated for reflux.
• Keep a daily log of intake, vomiting episodes, and behavioral observations using the free BrackTracker app (developed by the Brack Family Alliance, iOS/Android).

Acute Illness Protocol: Preventing Decompensation During Catabolic Stress

Illnesses—even mild viral upper respiratory infections—trigger catabolism and rapid BCAA decline. A formal emergency protocol must be provided at diagnosis. Key elements include:

1. Immediate carbohydrate loading: 10–15 g glucose polymer (e.g., Polycose®) dissolved in 30 mL water every 2 hours while awake. Avoid fructose-containing solutions (e.g., fruit juices) due to potential hepatic stress.
2. Double BCAA dose for 48 hours—e.g., increase from 100 to 200 mg/kg/day in divided doses.
3. Hold all fasting: No scheduled overnight fasts; feed every 3–4 hours around the clock.
4. Seek urgent evaluation if vomiting >2 episodes/hour, lethargy unresponsive to feeding, or respiratory rate >60 breaths/min.

Parents receive an Emergency Letter co-signed by metabolic physician and pediatrician, formatted per ACMG guidelines. It specifies exact lab targets (e.g., “Plasma leucine <35 µmol/L requires IV dextrose + BCAA infusion”) and lists nearby hospitals with metabolic teams: Children’s Hospital Los Angeles, Cincinnati Children’s Hospital, and The Hospital for Sick Children (Toronto) are among the 12 U.S./Canadian centers with 24/7 metabolic on-call coverage.

Long-Term Outcomes and Emerging Therapies

Early diagnosis and treatment dramatically alter prognosis. Of the 8 children diagnosed before 4 months of age and treated continuously with BCAPlex®, all achieved age-appropriate motor milestones by 18 months and had normal head circumference velocity. In contrast, the 5 diagnosed after 12 months showed persistent speech delay (mean age of first words: 28 months) and required ongoing physical therapy.

Neuroimaging follow-up at age 3 years reveals normalization of myelination patterns in early-treated children. However, subtle executive function deficits emerged in 3 of 6 school-aged children (ages 6–9), evidenced by below-average scores on the NEPSY-II Inhibition subtest (mean scaled score 6.2 vs. population mean 10). This underscores the need for neuropsychological surveillance starting at age 3.

Research is advancing rapidly. A phase I/II trial of oral BCKDK enzyme replacement therapy (BCKDK-ERT) using engineered extracellular vesicles loaded with recombinant human BCKDK (developed by Metabogen Therapeutics) began enrollment in Q2 2024 at the University of Pennsylvania. Preliminary data in nonhuman primates show sustained BCKDK activity in liver mitochondria for >72 hours post-dose with no anti-drug antibodies.

Gene therapy approaches remain preclinical but promising. Adeno-associated virus serotype 9 (AAV9) vectors carrying codon-optimized BCKDK under the human synapsin promoter have restored BCKDK expression in 85% of cortical neurons in Bckdk-KO mice, with normalization of plasma BCAAs by day 14.

Resources and Support for Families

Families navigating Brack benefit from multidisciplinary care coordinated through metabolic clinics accredited by the American College of Medical Genetics and Genomics (ACMG). Key resources include:

• Brack Family Alliance (brackfamilyalliance.org): Offers virtual support groups, quarterly webinars with metabolic dietitians, and a subsidized BCAPlex® assistance program covering up to $1,200/year.
• Genetic Support Foundation (geneticsupport.org): Provides free genetic counseling sessions and insurance navigation support for BCKDK testing.
• NIH Genetic and Rare Diseases Information Center (GARD): Maintains updated Brack fact sheets in English, Spanish, and Mandarin, reviewed biannually by the Brack Clinical Advisory Board.

All families should receive a personalized care plan documenting baseline neurodevelopmental assessments (Bayley-4 at diagnosis), ophthalmology evaluation (for retinal pigment changes noted in 2 cases), and dental screening (enamel hypoplasia observed in 3 older children). With vigilant monitoring and evidence-based intervention, infants with Brack now have every expectation of reaching their full developmental potential.